Core Insights - Daxor Corporation will host an investor conference call on March 6, 2025, at 4:30 p.m. ET to review financial results and corporate developments [1][2] - The call will feature President and CEO Michael Feldschuh and CFO Robert Michel, followed by a Q&A session for investors [2] - Daxor is recognized as a leader in blood volume measurement technology, with its BVA-100™ being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] Company Overview - Daxor Corporation focuses on blood volume testing innovation and has performed over 65,000 tests at leading hospital centers in the U.S., significantly impacting patient outcomes in heart failure and critical care [3] - The company is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] - Daxor's mission is to enhance healthcare through optimal fluid management via blood volume analysis, aiming for optimal blood volume for all patients [3]

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw." — Anonymous As we forge ahead into this pivotal year, Daxor remains laser-focused on our mi ...

Core Insights - Daxor Corporation reported a strong financial performance for 2024, achieving a 116.5% increase in revenue compared to 2023, driven by robust demand for its diagnostic systems [4] - The company is focused on transforming patient care through innovative blood volume analysis systems, with plans to launch a next-generation blood volume analyzer pending FDA approval [2][3] - Daxor's operating division achieved cash-flow break-even in Q1 of 2025, indicating positive operational cash flow [4] Financial Performance - The company reported a NAV of $7.25 per share for fiscal 2023, up from $7.08 in the previous year [1] - Daxor signed 12 new accounts in 2024, contributing to a 60.1% growth in the number of diagnostic kits sold year-over-year [4] - Record-breaking monthly kit revenue was observed in the first two months of 2025, reflecting accelerating adoption of Daxor's products [4] Strategic Developments - Daxor announced the imminent filing for its next-generation blood volume analyzer via the rapid 510(k) approval pathway with the FDA, enhancing clinical workflows in critical care settings [2] - The company secured a $2.5 million two-year contract from the Department of Defense, bolstering its commercial momentum [4] - Daxor received over $350,000 in NIH and Launch Tennessee grants to support ongoing research and development [4]

Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) testing services into a 735-bed healthcare facility in the Midwest, enhancing cardiovascular outpatient care [1][3] - The program specifically targets patients with heart failure, hypertension, and other cardiovascular conditions, emphasizing the importance of precise fluid management [2][3] - Daxor's BVA diagnostic provides clinicians with 98% accurate data, facilitating personalized fluid management that improves patient outcomes and reduces costs [3] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, having developed the BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - Daxor is involved in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care with the U.S. Department of Defense [4]

Core Insights - Daxor Corporation has expanded its blood volume analysis (BVA) technology at two major hospitals within New Jersey's largest academic health care system, anticipating continued sales growth throughout 2025 [1][2][3] - The implementation of on-site BVA analyzers at these hospitals will provide immediate access to precise blood volume measurements, enhancing fluid management and improving patient outcomes, particularly for heart failure and critical care patients [2][3] - The CEO of Daxor highlighted that the expansion reflects the effectiveness of the company's growth strategy and the increasing recognition of the importance of blood volume analysis technology in patient care [3] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with its BVA-100 being the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at leading hospital centers across the U.S., contributing to improved hospital performance metrics and significantly reducing mortality and readmissions in heart failure and critical care [3] - The company is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3]

Core Insights - Daxor Corporation announces groundbreaking studies from Duke University and Yale School of Medicine, highlighting the superiority of Blood Volume Analysis (BVA) technology over traditional pulmonary artery pressure monitoring for fluid management in heart failure patients [1][3] - The studies reveal that direct blood volume measurement provides critical insights for optimizing therapy, challenging the reliance on pressure measurements as a proxy for fluid status [3][6] Daxor Corporation Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100® diagnostic test, which is FDA-cleared for accurate quantification of blood volume status [4] - Over 65,000 tests have been conducted across leading hospitals in the U.S., significantly improving outcomes in heart failure and critical care by reducing mortality and readmissions [4] Study Findings - The Duke study found no correlation between pulmonary artery pressure readings and actual blood volume measured by BVA, indicating the limitations of current monitoring methods [6] - Yale's research demonstrated the effectiveness of BVA in detecting volume shifts and provided new insights into the diuretic mechanism of action, potentially improving treatment for millions on diuretic therapy [6] Implications for the Industry - BVA technology is positioned as the most accurate method for assessing fluid status, suggesting that current home monitoring devices may have significant limitations [6] - The new understanding of diuretic therapy, supported by BVA data, could enhance treatment outcomes and provide valuable evidence for researchers in the field [6]

Group 1: Company Overview - Daxor Corporation is the global leader in blood volume measurement technology, focusing on blood volume testing innovation [4] - The company developed the BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] Group 2: Technology Impact - Daxor's blood volume analysis (BVA) has shown a significant impact on patient outcomes, altering fluid and red blood cell interventions in 44% of cases and reducing mortality by 66% in surgical intensive care units [2] - The technology also contributes to decreased hospital stays and ventilator days, enhancing healthcare economics [2] Group 3: Industry Context - The Society for Critical Care Medicine (SCCM) is the largest nonprofit medical organization dedicated to promoting excellence in critical care, with members in over eighty countries [3] - The SCCM 2025 Critical Care Congress will provide a strategic platform for Daxor to showcase its innovative solutions [2][3]

Core Insights - Daxor Corporation has published a significant case series in JACC: Case Reports, highlighting the importance of blood volume analysis in heart failure treatment, identifying a specific phenotype characterized by expanded blood volume overload and elevated red blood cells [1][2] - The study evaluated 179 advanced heart failure patients, revealing that 20% (36 patients) exhibited the hypervolemia/polycythemia phenotype, with four patients undergoing therapeutic phlebotomy [2][5] Company Overview - Daxor Corporation (NASDAQ:DXR) is a leader in blood volume measurement technology, known for its BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] - Over 65,000 tests have been conducted at major U.S. hospitals, significantly improving outcomes in heart failure and critical care by reducing mortality and readmissions [3] Clinical Findings - The BVA analysis detected critical volume issues that standard blood tests missed, affecting 700,000 to 1,400,000 heart failure patients in the U.S. [5] - Patients with the identified phenotype face worse clinical outcomes, including higher risks of stroke and blood clots if untreated [5] - Therapeutic phlebotomy guided by BVA resulted in significant symptom improvement with no hospitalizations or deaths over a 12-month period [5]

Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions Oak Ridge, TN, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor’s Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemodynamic measur ...

Healthcare Providers Embrace Blood Volume Analysis (BVA) in Nephrology and Heart Failure Outpatient Care Oak Ridge, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces expansion of its ezBVA Lab service to two new health systems. Daxor's ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement coverage across ...